3-FEA: Difference between revisions

Line 72:

==Toxicity and harm potential==

The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is likely because 3-FEA has an extremely ~~short~~ history of human usage, becoming available ~~only~~ in mid-2016. Early anecdotal reports from people within the community who have tried 3-FEA ~~suggests~~ that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (~~but~~ nothing can be completely guaranteed).

The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is likely because 3-FEA has an extremely brief history of human usage, first becoming available in mid-2016. Early anecdotal reports from people within the community who have tried 3-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (although nothing can be completely guaranteed).

Likely due to its properties as a [[serotonin]]-releasing entactogen, it is possible 3-FEA may display unusually high affinity for the 5-HT<sub>2B</sub> receptor, which like [[MDMA]] and fenfluramine would make it would be cardiotoxic with long-term use,<ref>Huang, X. P., Setola, V., Yadav, P. N., Allen, J. A., Rogan, S. C., Hanson, B. J., ... & Roth, B. L. (2009). Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. ''Molecular Pharmacology'', 76(4), 710-722. https://doi.org/10.1161/01.CIR.102.23.2836</ref> as seen in other 5-HT<sub>2B</sub> agonists such as [https://en.wikipedia.org/wiki/Fenfluramine fenfluramine] and [[MDMA]].

@@ Line 72: / Line 72: @@
 ==Toxicity and harm potential==
 {{Further|Research chemicals#Toxicity and harm potential}}
-The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is likely because 3-FEA has an extremely short history of human usage, becoming available only in mid-2016. Early anecdotal reports from people within the community who have tried 3-FEA suggests that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).
+The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is likely because 3-FEA has an extremely brief history of human usage, first becoming available in mid-2016. Early anecdotal reports from people within the community who have tried 3-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (although nothing can be completely guaranteed).
 Likely due to its properties as a [[serotonin]]-releasing entactogen, it is possible 3-FEA may display unusually high affinity for the 5-HT<sub>2B</sub>  receptor, which like [[MDMA]] and fenfluramine would make it would be cardiotoxic with long-term use,<ref>Huang, X. P., Setola, V., Yadav, P. N., Allen, J. A., Rogan, S. C., Hanson, B. J., ... & Roth, B. L. (2009). Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. ''Molecular Pharmacology'', 76(4), 710-722. https://doi.org/10.1161/01.CIR.102.23.2836</ref> as seen in other 5-HT<sub>2B</sub> agonists such as [https://en.wikipedia.org/wiki/Fenfluramine fenfluramine] and [[MDMA]].